Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback